What Next for Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN) Stock After Decrease in Shorted Shares?

March 14, 2018 - By Marguerite Chambers

 What Next for Urogen Pharma LTD.   Ordinary Shares (NASDAQ:URGN) Stock After Decrease in Shorted Shares?

The stock of Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN) registered a decrease of 10.08% in short interest. URGN’s total short interest was 106,100 shares in March as published by FINRA. Its down 10.08% from 118,000 shares, reported previously. With 222,900 shares average volume, it will take short sellers 1 days to cover their URGN’s short positions. The short interest to Urogen Pharma LTD. – Ordinary Shares’s float is 1.25%.

The stock increased 3.53% or $1.96 during the last trading session, reaching $57.54. About 76,493 shares traded. Urogen Pharma Ltd. (NASDAQ:URGN) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company has market cap of $875.46 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy. It has a 248.02 P/E ratio. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

More notable recent Urogen Pharma Ltd. (NASDAQ:URGN) news were published by: Globenewswire.com which released: “UroGen Pharma Welcomes New Board Member Kate Falberg” on April 24, 2017, also Globenewswire.com with their article: “UroGen Pharma Reports Third Quarter 2017 Financial Results and Recent …” published on November 14, 2017, Globenewswire.com published: “UroGen Pharma Reports Second Quarter 2017 Financial Results and Recent …” on August 14, 2017. More interesting news about Urogen Pharma Ltd. (NASDAQ:URGN) were released by: Globenewswire.com and their article: “UroGen Pharma Announces Pricing of Initial Public Offering” published on May 03, 2017 as well as Globes.Co.Il‘s news article titled: “UroGen Pharma raises $58.2m in Nasdaq IPO” with publication date: May 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.